Barriers to Human Papillomavirus Vaccine Series Completion among Insured Individuals in an Integrated Healthcare Setting.

Autor:	Kamineni A; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA., Blasi PR; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA., Gundersen GD; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA., Oliver M; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA., Dunn JB; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA., Galloway DA; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Madeleine MM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jazyk:	angličtina
Zdroj:	Infectious diseases [Infect Dis (Auckl)] 2021 May 20; Vol. 14, pp. 11786337211018712. Date of Electronic Publication: 2021 May 20 (Print Publication: 2021).
DOI:	10.1177/11786337211018712
Abstrakt:	Introduction: Infection with certain types of human papillomavirus (HPV) can lead to cervical cancer as well as other cancers in both men and women. However, the requirement for multiple doses may limit the vaccine's effectiveness for cancer prevention. We conducted a pilot study to investigate barriers to HPV vaccine series completion among members of an integrated healthcare system with clinical documentation of only 1 dose. Methods: We surveyed parents or legal guardians of 11-17-year-old girls (n = 10) and boys (n = 18), as well as 18-31-year-old women (n = 20) and men (n = 9), about their reasons for not completing the HPV vaccine series. Results: Most participants (70.2%) were non-Hispanic white. Among parents of children, commonly reported barriers to HPV vaccine series completion included not being aware or informed of the need for additional doses (28.6%), as well as the inconvenience of returning for additional doses (17.9%). Concerns about the HPV vaccine or vaccines in general were more common among parents of girls (30.0%) compared with parents of boys (16.7%). Among adults, barriers to HPV vaccine series completion included the inconvenience of returning for additional doses (31.0%), not being aware or informed of the need for additional doses (10.3%), and forgetting (10.3%). Conclusion: Our findings suggest that clinicians and healthcare systems can play a greater role in promoting awareness of the multiple-dose requirement, addressing vaccine concerns, and increasing opportunistic vaccination in a variety of settings. Increasing these efforts may facilitate HPV vaccine completion and increase its effectiveness in cancer prevention. Competing Interests: Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu